Share:
Dr. John Kovach, the CEO and founder of Lixte Biotechnology Holdings, Inc., expressed excitement for his company’s first-in-class protein phosphatase inhibitor, LB-100 as a new addition to cancer treatment at the Benzinga Global Small Cap Business Conference on May 13, 2021.
Lixte Biotechnology (NASDAQ: LIXT), a drug discovery company, created and patented a series of novel drugs that enhance the effectiveness of standard anti-cancer therapy in a number of animal models.
More than 40 preclinical studies report that Lixte’s LB-100 increases the anti-tumor activity of standard chemotherapy, radiotherapy and immunotherapy without increasing toxicity.
Dr. Kovach noted that Lixte’s extensive international patent portfolio includes patents for LB-100 and its potential clinical applications based on lead compounds and some other drivers of those compounds. “We’re not aware of any competition at the moment, but we expect we’ll be getting some soon,” he said, “but w
Minnesota
United-states
Mayo-clinic-in-rochester
John-kovach
Lixte-biotechnology-holdings
Lixte-biotechnology-holdings-inc
Us-oncology-network
Benzinga-global-small-cap-business-conference
Mayo-clinic
Myelodysplastic-syndromes
மினசோட்டா
ஒன்றுபட்டது-மாநிலங்களில்